CCL2 and breast carcinoma: Moreover, CCL2 secreted by TAMs has been linked to the induction of tamoxifen resistance in breast cancer cells through the PI3K/Akt/mammalian target of rapamycin (mTOR) pathway (Li et al., 2020).